Literature DB >> 31407092

Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.

Michelle B Mulder1, Kenneth G Proctor1, Evan J Valle1, Alan S Livingstone1, Dao M Nguyen1, Robert M Van Haren2.   

Abstract

BACKGROUND: Rates of venous thromboembolism are increased in thoracic malignancy; however, coagulation patterns are not established. We hypothesize that patients with esophageal and lung malignancy have similar hypercoagulable pre- and postoperative profiles as defined by rotational thromboelastometry (ROTEM).
METHODS: Prospective study was conducted in 47 patients with esophageal and lung cancer undergoing surgical resection. ROTEM evaluated pre/postoperative coagulation status.
RESULTS: Patients with thoracic malignancy were hypercoagulable by ROTEM, but not by conventional coagulation tests. Preoperative hypercoagulability was higher in lung versus esophageal cancer (64 vs. 16%, p = 0.001). Lung cancer patients that were hypercoagulable preoperatively demonstrated decreased maximum clot firmness (MCF) (p = 0.044) and increased clot time (p = 0.049) after surgical resection, suggesting reversal of hypercoagulability. Resection of esophageal cancer increased hypercoagulability (16 vs. 56%, p = 0.002) via elevated MCF (reflecting platelet activity). Hypercoagulability remained at follow-up clinic for both lung and esophageal cancer patients.
CONCLUSIONS: Hypercoagulability in patients with lung malignancies reversed following complete surgical resection, whereas hypercoagulability occurred only postoperatively in those with esophageal malignancies. In both, hypercoagulability was associated with fibrin and platelet function.

Entities:  

Mesh:

Year:  2019        PMID: 31407092     DOI: 10.1007/s00268-019-05123-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  38 in total

1.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Long-term coagulation changes after resection of thoracoabdominal malignancies.

Authors:  Robert M Van Haren; Evan J Valle; Chad M Thorson; Gerardo A Guarch; Jassin M Jouria; David M Andrews; Danny Sleeman; Joe U Levi; Alan S Livingstone; Kenneth G Proctor
Journal:  J Am Coll Surg       Date:  2014-01-15       Impact factor: 6.113

3.  Venous thromboembolism events after thoracic surgery: global steps toward prevention.

Authors:  Robert M Van Haren; Virginia R Litle
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 4.  The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery.

Authors:  Hui Li; Gening Jiang; Servet Bölükbas; Chun Chen; Haiquan Chen; Keneng Chen; Jun Chen; Xiangli Cui; Wentao Fang; Shugeng Gao; Sebastien Gilbert; Jianhua Fu; Xiangning Fu; Yasuhiro Hida; Shanqing Li; Xiaofei Li; Yin Li; Hecheng Li; Yongjun Li; Deruo Liu; Lunxu Liu; Jianxing He; Jie He; Giuseppe Marulli; Hiroyuki Oizumi; Marc de Perrot; René Horsleben Petersen; Yaron Shargall; Alan Sihoe; Qunyou Tan; Qun Wang; Shun Xu; Mei Yang; Yuanhua Yang; Zhentao Yu; Lanjun Zhang; Xun Zhang; Heng Zhao; Xiuyi Zhi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer.

Authors:  Krista J Hachey; Philip D Hewes; Liam P Porter; Douglas G Ridyard; Pamela Rosenkranz; David McAneny; Hiran C Fernando; Virginia R Litle
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-15       Impact factor: 5.209

6.  Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients.

Authors:  Helene M Sterbling; Amy K Rosen; Krista J Hachey; Niru S Vellanki; Philip D Hewes; Sowmya R Rao; Emma Pinjic; Hiran C Fernando; Virginia R Litle
Journal:  Ann Thorac Surg       Date:  2018-02-01       Impact factor: 4.330

7.  Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer.

Authors:  M L Papa; F Capasso; L Pudore; S Torre; S Mango; V Russo; P Delrio; R Palaia; F Ruffolo; M D d'Eufemia; D De Lucia; M Napolitano; P Di Micco; V Parisi
Journal:  Exp Oncol       Date:  2007-06

8.  Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography.

Authors:  O Meltem Akay; Zeki Ustuner; Zerrin Canturk; Fezan Sahin Mutlu; Zafer Gulbas
Journal:  Med Oncol       Date:  2008-11-20       Impact factor: 3.064

9.  Application of ROTEM to assess hypercoagulability in patients with lung cancer.

Authors:  N A Davies; N K Harrison; A Sabra; M J Lawrence; S Noble; S J Davidson; V J Evans; R H K Morris; K Hawkins; P R Williams; P A Evans
Journal:  Thromb Res       Date:  2015-03-19       Impact factor: 3.944

10.  Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial.

Authors:  Thomas Decker Christensen; Henrik Vad; Søren Pedersen; Kåre Hornbech; Nora Elisabeth Zois; Peter B Licht; Mads Nybo; Anne-Mette Hvas
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

View more
  2 in total

1.  Risk factors for venous thromboembolism and evaluation of the modified Caprini score in patients undergoing lung resection.

Authors:  Songping Cui; Shuo Chen; Hui Li; Lihui Ke; Yi Liu; Ruiheng Jiang; Bin Hu; Tong Li; Yang Wang; Jinbai Miao; Wenqian Zhang
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

2.  Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery.

Authors:  Luca Spiezia; Marco Cuzzolin; Hernandez Elssy; Guido Di Gregorio; Elena Campello; Federico Rea; Andrea Zuin; Paolo Simioni
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.